- $12.45m
- $3.86m
- $5.21m
Plus Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
Brief: AIGH Capital Management Reports Passive Stake Of 9.9% In Plus Therapeutics
Brief: Plus Therapeutics Inc - On May 31, Drew $3.3 Mln On Existing Margin Loan Facility With Pershing LLC
U.S. RESEARCH ROUNDUP-Asana, GE Vernova, New Gold
Plus Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Plus Therapeutics Q1 Net Income USD -3.261 Million
Plus Therapeutics Inc expected to post a loss of $1.09 a share - Earnings Preview
Plus Therapeutics Inc expected to post a loss of $1.09 a share - Earnings Preview
Brief: Plus Therapeutics Announces Validation, Clinical Implementation Of CSF-01 Leptomeningeal Cancer Cell Diagnostic
Brief: Plus Therapeutics Received Letter From Nasdaq on March 8 Notifying Co That It No Longer Complies With Requirement Under Nasdaq Listing Rule 5550(B)(1)
Brief: Plus Therapeutics Completes Dosing In Cohort 5 Of Phase 1 Trial Of Rhenium Obisbemeda In Leptomeningeal Metastases
U.S. RESEARCH ROUNDUP-Duolingo, Mid-America Apartment Communities, Nextracker
Plus Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Plus Therapeutics Reports Fourth Quarter Results
Brief: Plus Therapeutics FY Net Income USD -13.316 Million
Plus Therapeutics Inc expected to post a loss of $1.07 a share - Earnings Preview
Plus Therapeutics Inc expected to post a loss of $1.07 a share - Earnings Preview
Plus Therapeutics Inc expected to post a loss of $1.07 a share - Earnings Preview